AUTHORS
Szumam Liu Gilbert, PhD, Anlun Li Jr, PhD2, Xiaxin Dong, M.S.3, X. Long Zheng, MD, PhD4
AFFILIATIONS
1 The University of Kansas Medical Center, Kansas City, Kansas, United States
2 The University of Kansas Medical Center, Kansas City, Kansas, United States
3 The University of Kansas Medical Center, Kansas City, Kansas, United States
4 The University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background: ADAMTS13 is a metalloprotease that cleaves ultra-large von Willebrand factor (ULVWF) multimers, thus preventing pathological platelet adhesion and microvascular thrombosis. Severe deficiency of plasma ADAMTS13 activity results in a potentially fatal blood clot disorder thrombotic thrombocytopenic purpura. Moderate deficiency of ADAMTS13 activity is associated with adverse outcomes in patients with thromboinflammatory disorders including sepsis, trauma, infection, and heparin-induced thrombocytopenia, etc. ADAMTS13 is produced in at least two distinct types of cells: hepatic stellate cells (HSCs), long regarded as the source of the circulating ADAMTS13 pool and endothelial cells (ECs), positioned to cleave nascent VWF polypeptide and ULVWF strings locally at the sites of their release. Yet, this source attribution rests on the expression and localization data alone and has never been rigorously tested and the functionality of each cellular source of ADAMTS13 is not known. To bridge these knowledge gaps, we created cell-type-specific Adamts13 conditional knockout (cKO) mice — Lrat-Cre (HSC-specific) and Tek-Cre (EC-specific) — enabling selective deletion of one source while sparing the other. We began to test the contribution of each cellular source of ADAMTS13 to protection against microvascular thrombosis under various pathological conditions.
Methods: A floxed Adamts13 allele (loxP sites flanking exon 3) was crossed to Lrat-Cre or Tek-Cre to generate HSC-specific and EC-specific conditional knockout (cKO) mice, respectively. We used global-KO and Cre-negative floxed littermates as controls. At baseline, plasma ADAMTS13 antigen was quantified by ELISA, plasma ADAMTS13 activity by FRETS-VWF73, and VWF multimer distribution by agarose gel electrophoresis and immunoblotting. Mice were then challenged with lipopolysaccharide (LPS) (4 mg/kg, IP) and platelet counts were determined at 0, 3, 6, and 24 h following LPS challenge.
Results: Compared with the control mice, heterozygous HSC-specific cKO significantly reduced plasma ADAMTS13 antigen (0.47 ± 0.08 vs 0.71±0.18 µg/mL) and activity (0.40 ± 0.06 vs 0.80 ± 0.06 U/mL, mean±SD), whereas heterozygous EC-specific cKO preserved both ADAMTS13 antigen (0.62 ± 0.13 µg/mL) and activity (0.60 ± 0.07 U/mL). Further reduction of plasma ADAMTS13 activity to 0.10 ± 0.02 U/mL in the homozygous HSC-specific cKO mice, suggesting that HSCs are the primary source of circulating ADAMTS13 pool. Interestingly, both heterozygous cKO mouse lines showed markedly elevated ratio of ultra-large/low (H/L) molecular weight VWF multimers (18–21% vs 2% in controls), indicating that each compartment contributes to regulate systemic VWF multimer homeostasis. Under LPS challenge, platelet counts fell by 25–30% across all groups at 3 h, and both heterozygous cKO lines continued to fall below 50% by 6 h. By 24 h, the platelet counts in heterozygous HSC-cKO mice partially recovered (to 460×109/L) while the platelet counts in heterozygous EC-cKO mice remained significantly low (290×109/L), despite the normal to increased levels of plasma ADAMTS13 activity. In parallel, the ultra large VWF multimers in the heterozygous EC-cKO mice peaked at 3 h (H/L ratio of ~14%) then fell to the lowest in all groups by 24 h (H/L ratio ~4.8%), a pattern consistent with increased consumption of ultra large VWF multimers in the formation of microvascular thrombosis rather than ADAMTS13-related degradation or clearance of VWF.
Conclusions: A selective deletion of EC- versus HSC-specific ADAMTS13 reveals a distinct, but non-redundant function of ADAMTS13 in vivo. The EC-derived ADAMTS13 may confer a local microvascular protection invisible to plasma-based ADAMTS13 activity assays. The HSC-derived ADAMTS13 contributes primarily to the circulating pool of ADAMTS13. Both sources are critical for the regulation of VWF homeostasis. The EC-derived ADAMTS13 appears to exhibit a much greater protection against LPS-induced thrombocytopenia and perhaps microvascular thrombosis. Thus, an assay of plasma ADAMTS13 activity alone may not reflect the organ-level vulnerability for thrombosis and inflammation. Our results may shed new light on the biology of ADAMTS13 and how ADAMTS13 deficiency should be assessed and addressed under thromboinflammatory conditions.
Abbrevation: HSC, hepatic stellate cells; EC, endothelila cells; cKO, conditional knockout; LPS, lipopolysaccharide
DISCLOSURES
Szumam Liu Gilbert, PhD: No relevant conflicts of interest to declare.